Clinical Trial

CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC

Name: CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC — clinical trial record (NCT07449065)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Completed

View on ClinicalTrials.gov →

Summary

This retrospective multicenter study aims to evaluate whether radiographic microvascular invasion (MVI) status can predict treatment response in patients with intermediate-stage hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) versus TACE alone.

Trial Details

NCT Number	NCT07449065
Lead Sponsor	First Affiliated Hospital, Sun Yat-Sen University
Conditions	Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization, Microvascular Invasion (MVI), Tyrosine Kinase Inhibitors
Enrollment	324 participants
Start Date	2018-06-01
Primary Completion	2025-10-31 (estimated)
Study Completion	2025-10-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-04